BC
GBT

Brookfield Corp’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Brookfield Corp’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-90,463
Closed -$2.89M – 819
2022
Q2 		$2.89M Buy
+90,463
New +$2.65M 0.01% 343

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Brookfield Corp's GBT Position: Q3 2022 in Review

Brookfield Corp sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 90,463 shares — an estimated $2.89M sold.

Brookfield Corp first reported a position in GBT in Q2 2022 and held it in 1 quarter. The position peaked at $2.89M in Q2 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Brookfield Corp reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Brookfield Corp sold 90,463 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $2.89M.
  • Brookfield Corp first reported a position in Global Blood Therapeutics, Inc. in Q2 2022 and held it in 1 quarter.
  • Brookfield Corp's Global Blood Therapeutics, Inc. position peaked at $2.89M in Q2 2022.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Brookfield Corp's 13F filing for Q3 2022, filed 14 Nov 2022.